Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001847367-24-000005
Filing Date
2024-11-13
Accepted
2024-11-13 16:24:34
Documents
80
Period of Report
2024-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q tmb-20240930x10q.htm   iXBRL 10-Q 2734980
2 EX-31.1 tmb-20240930xex31d1.htm EX-31.1 15490
3 EX-31.2 tmb-20240930xex31d2.htm EX-31.2 14994
4 EX-32.1 tmb-20240930xex32d1.htm EX-32.1 9785
5 EX-32.2 tmb-20240930xex32d2.htm EX-32.2 9214
  Complete submission text file 0001847367-24-000005.txt   10133638

Data Files

Seq Description Document Type Size
6 EX-101.SCH tmb-20240930.xsd EX-101.SCH 66824
7 EX-101.CAL tmb-20240930_cal.xml EX-101.CAL 54211
8 EX-101.DEF tmb-20240930_def.xml EX-101.DEF 267315
9 EX-101.LAB tmb-20240930_lab.xml EX-101.LAB 582410
10 EX-101.PRE tmb-20240930_pre.xml EX-101.PRE 449701
83 EXTRACTED XBRL INSTANCE DOCUMENT tmb-20240930x10q_htm.xml XML 1682310
Mailing Address 280 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080
Business Address 280 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080 650-231-6625
ALUMIS INC. (Filer) CIK: 0001847367 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-42143 | Film No.: 241454708
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)